Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 11, 2023

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions

HypoparathyroidismOsteoporosisFractures, BoneOther Disease

Interventions

DRUG

EBP05

Oral tablets

DRUG

Forteo 20 mg

Subcutaneous injection

DRUG

EBP11

Oral tablets

DRUG

EBP22

Oral tablets

Trial Locations (1)

Clinical Research Center Hadassah Ein Kerem Medical Center, Jerusalem